Understanding MYH9-Related Disorder
MYH9-Related Disorder is a rare inherited condition causing large platelets and low platelet counts (macrothrombocytopenia), which in some patients is also associated with kidney disease, hearing loss, or cataracts.
- Autosomal dominant inheritance
- Macrothrombocytopenia
- Possible kidney, ear, eye involvement
- Most Common In
- Both sexes (autosomal dominant)
- Causative Gene
- MYH9
- Key Feature
- Giant platelets with low platelet count
- Advanced Therapies
- Kidney-protective therapy, hearing support
Condition Overview
MYH9-Related Disorder (MYH9-RD) is a rare autosomal dominant condition caused by mutations in the MYH9 gene, which encodes a protein important for platelet formation and the function of certain cells in the kidney, inner ear, and eye. The disorder was previously described as several separate conditions — May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome — which are now understood to represent a spectrum of the same underlying genetic disorder.
Types and Historical Classification
Before genetic testing clarified the shared cause, MYH9-RD was described under several historical syndrome names based on which features were present.
Symptoms and Signs
Symptoms vary widely between patients, ranging from isolated mild bleeding tendency to multisystem involvement.
Causes and Risk Factors
MYH9-Related Disorder is caused by inherited mutations in the MYH9 gene, which plays a role in cell structure and function across multiple organ systems.
Diagnosis and Investigations
Diagnosis requires distinguishing MYH9-RD from other causes of low platelet count, given the risk of unnecessary treatment if misdiagnosed as immune thrombocytopenia.
Risk Stratification
Risk in MYH9-RD is best understood by which organ systems are involved, often correlating with the specific gene mutation.
Standard Treatment
There is no specific cure; management focuses on monitoring and treating organ-specific complications as they arise.
Advanced & Emerging Therapies
Management increasingly draws on therapies developed for chronic kidney disease and hearing loss in patients with significant organ involvement.
Renal Protective Therapy
ACE inhibitors / ARBs
Used to slow progression of proteinuric kidney disease in MYH9-RD.
Renal Replacement Therapy
Dialysis or kidney transplantation
Considered for patients who progress to advanced kidney failure.
Genetic Risk Stratification
Mutation-specific prognostic counseling
Helps tailor monitoring intensity based on which part of the MYH9 gene is affected.
Biomarkers & Monitoring
Genetic and organ-specific markers guide diagnosis and ongoing surveillance.
When to Seek a Second Opinion
A second opinion can help avoid misdiagnosis and ensure appropriate multisystem monitoring.
Clinical Trials & Research
Prognosis & Outcomes
Prognosis depends heavily on which organ systems are affected; many patients with isolated macrothrombocytopenia have an excellent long-term outlook, while those with kidney involvement require closer monitoring.
Supportive Care
Supportive care focuses on regular monitoring and early management of organ-specific complications.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with MYH9-Related Disorder access specialist hematology and nephrology review and coordinate multidisciplinary monitoring for kidney, hearing, and vision involvement.
Get a free case reviewFrequently Asked Questions
It is a rare inherited disorder causing large platelets and low platelet counts, which in some patients is also linked to kidney disease, hearing loss, or cataracts.
These are historical names for what is now understood to be a single disorder, MYH9-Related Disorder, with varying organ involvement.
Diagnosis combines blood smear findings, specialized protein staining, and genetic testing of the MYH9 gene.
Yes, it is sometimes misdiagnosed as immune thrombocytopenia due to the low platelet count, which can lead to unnecessary treatment.
No, only some patients develop kidney involvement, often related to where the mutation occurs within the MYH9 gene.
Yes, it follows an autosomal dominant pattern, meaning a single affected gene copy from one parent can cause the disorder.
Regular kidney function tests, hearing tests, and eye examinations are recommended alongside routine blood count monitoring.
There is no cure, but organ-specific complications can be actively monitored and managed to improve long-term outcomes.
Yes, some patients develop progressive sensorineural hearing loss over time, which can be monitored with regular audiometry.
Yes. CancerFax assists with medical report review, second opinion coordination, and connecting patients with specialist centers for multidisciplinary care, including international coordination where relevant.
Get Expert Guidance on MYH9-Related Disorder
Send your medical reports for a specialist review and coordinate multidisciplinary monitoring for MYH9-RD.